Dr. Andreadis on the Treatment of Relapsed DLBCL

Charalambos (Babis) Andreadis, MD, MSCE
Published: Monday, Dec 03, 2018



Charalambos (Babis) Andreadis, MD, MSCE, associate professor of clinical medicine, Department of Medicine, University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discusses the treatment of patients with relapsed diffuse large B-cell lymphoma (DLBCL).

The relapsed setting of DLBCL is an area of clinical unmet need. One-third of patients in this setting can benefit, or even be cured, by transplant, but additional therapies are needed, Andreadis says. There are many patients who are ineligible for transplant or do not respond well enough to chemotherapy to benefit. Chimeric antigen receptor (CAR) T-cell therapy may be an option for these patients.  

Results from the phase II JULIET study presented at the 2018 ASH Annual Meeting showed that the CAR T-cell therapy tisagenlecleucel (Kymriah) continued to demonstrate durable objective response rates (ORR) with a median of 19 months of follow-up for patients with relapsed or refractory DLBCL. The ORR in this updated analysis was 54% (95% CI, 41%-62%) with the CD19-targeted CAR T-cell therapy.   
SELECTED
LANGUAGE


Charalambos (Babis) Andreadis, MD, MSCE, associate professor of clinical medicine, Department of Medicine, University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discusses the treatment of patients with relapsed diffuse large B-cell lymphoma (DLBCL).

The relapsed setting of DLBCL is an area of clinical unmet need. One-third of patients in this setting can benefit, or even be cured, by transplant, but additional therapies are needed, Andreadis says. There are many patients who are ineligible for transplant or do not respond well enough to chemotherapy to benefit. Chimeric antigen receptor (CAR) T-cell therapy may be an option for these patients.  

Results from the phase II JULIET study presented at the 2018 ASH Annual Meeting showed that the CAR T-cell therapy tisagenlecleucel (Kymriah) continued to demonstrate durable objective response rates (ORR) with a median of 19 months of follow-up for patients with relapsed or refractory DLBCL. The ORR in this updated analysis was 54% (95% CI, 41%-62%) with the CD19-targeted CAR T-cell therapy.   



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 14th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®Apr 30, 20192.0
Oncology Consultations®: The Advancing Role of CAR T-Cell Therapies in Hematologic MalignanciesApr 30, 20191.5
Publication Bottom Border
Border Publication
x